Federal Circuit reverses its earlier ruling in Life Technologies v Promega
The US Court of Appeals for the Federal Circuit has reversed its findings in Life Technologies v Promega, nine months after the US Supreme Court limited overseas patent infringement.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
22 February 2017 The US Supreme Court today ruled that supplying a single component of a multi-component invention for manufacture abroad does not constitute patent infringement.
23 February 2017 The US Supreme Court has “left more questions than it answered” in the Life Technologies v Promega ruling, which was handed down yesterday, according to lawyers.
22 February 2017 The US Supreme Court today ruled that supplying a single component of a multi-component invention for manufacture abroad does not constitute patent infringement.
23 February 2017 The US Supreme Court has “left more questions than it answered” in the Life Technologies v Promega ruling, which was handed down yesterday, according to lawyers.
22 February 2017 The US Supreme Court today ruled that supplying a single component of a multi-component invention for manufacture abroad does not constitute patent infringement.
23 February 2017 The US Supreme Court has “left more questions than it answered” in the Life Technologies v Promega ruling, which was handed down yesterday, according to lawyers.